Epigenetics in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 27, Issue 1, 2015, Pages 76-82

  Klein, Kerstin ^a   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bromodomain protein; DNA methylation; Histone; Rheumatoid arthritis

Indexed keywords

HISTONE DEACETYLASE; POLYAMINE;

DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC RISK; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; GENETIC EPIGENESIS; GENETICS; HEALTH; METABOLISM; MORBIDITY; PROCEDURES; RISK FACTOR;

ARTHRITIS, RHEUMATOID; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GLOBAL HEALTH; HUMANS; MORBIDITY; RISK FACTORS;

EID: 84918564948     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000128     Document Type: Review

References (43)

1. Padyukov L, Seielstad M, Ong RT, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011; 70:259-265.
2. Klareskog L, Gregersen PK, Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis 2010; 69:2062-2066.
3. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:141-153.
4. Musselman CA, Lalonde ME, Cote J, et al. Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol 2012; 19:1218-1227.
5. Filkova M, Jungel A, Gay RE, et al. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs 2012; 26:131-141.
6. Zhang K, Shi ZM, Chang YN, et al. The ways of action of long noncoding RNAs in cytoplasm and nucleus. Gene 2014; 547:1-9.
7. Song J, Kim D, Han J, et al. PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. Clin Exp Med 2014; Epub ahead of print.
8. Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13:484-492.
9. Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:3613-3622.
10. Liu CC, Fang TJ, Ou TT, et al. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol Lett 2011; 135:96-99.
11. Nakano K, Whitaker JW, Boyle DL, et al. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2013; 72:110-117.
12. Karouzakis E, Gay RE, Gay S, et al. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2012; 64:1809-1817.
13. Neidhart M, Karouzakis E, Jungel A, et al. Inhibition of spermidine/spermine n1-acetyltransferase activity: A new therapeutic concept in rheumatoid arthritis. Arthritis Rheumatol 2014; 66:1723-1733.
14. Park SH, Kim SK, Choe JY, et al. Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis. Mol Cells 2013; 35:298-304.
15. Zhou Q, Long L, Shi G, et al. Research of the methylation status of miR-124a gene promoter among rheumatoid arthritis patients. Clin Dev Immunol 2013; 2013:524204.
16. Cribbs AP, Kennedy A, Penn H, et al. Regulatory T cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the IDO pathway. Arthritis Rheumatol 2014; 66:2344-2354.
17. Klein K, Gay S. Epigenetic modifications in rheumatoid arthritis, a review. Curr Opin Pharmacol 2013; 13:420-425.
18. McGee-Lawrence ME, Westendorf JJ. Histone deacetylases in skeletal development and bone mass maintenance. Gene 2011; 474:1-11.
19. Rajendran P, Williams DE, Ho E, et al. Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol 2011; 46:181-199.
20. Toussirot E, Wendling D, Herbein G, et al. Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. Joint Bone Spine 2014; Epub ahead of print.
21. Ospelt C, Camici GG, Engler A, et al. Smoking induces transcription of the heat shock protein system in the joints. Ann Rheum Dis 2014; 73:1423-1426.
22. Engler A, Niederer F, Klein K, et al. SIRT6 regulates the cigarette smokeinduced signalling in rheumatoid arthritis synovial fibroblasts. J Mol Med (Berl) 2014; 92:757-767.
23. Lee HS, Ka SO, Lee SM, et al. Overexpression of sirtuin 6 suppresses inflammatory responses and bone destruction in mice with collagen-induced arthritis. Arthritis Rheum 2013; 65:1776-1785.
24. Niederer F, Ospelt C, Brentano F, et al. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 2011; 70:1866-1873.
25. Choo QY, Ho PC, Tanaka Y, et al. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 2010; 49:1447-1460.
26. Gillespie J, Savic S, Wong C, et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012; 64:418-422.
27. Grabiec AM, Korchynskyi O, Tak PP, et al. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71:424-431.
28. Grabiec AM, Krausz S, de Jager W, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010; 184:2718-2728.
29. Ahmed S, Riegsecker S, Beamer M, et al. Largazole, a class I histone deacetylase inhibitor, enhances TNF-alpha-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts. Toxicol Appl Pharmacol 2013; 270:87-96.
30. Hsieh IN, Liou JP, Lee HY, et al. Preclinical antiarthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis 2014; 5:e1166.
31. Li M, Liu X, Sun X, et al. Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes. Inflammation 2013; 36:888-896.
32. Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013; 31:142-147.
33. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506:376-381.
34. Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013; 45:124-130.
35. Glant TT, Besenyei T, Kadar A, et al. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum 2013; 65:1725- 1735.
36. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010; 468:1067-1073.
37. Gallenkamp D, Gelato KA, Haendler B, et al. Bromodomains and their pharmacological inhibitors. Chem Med Chem 2014; 9:438-464.
38. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468:1119-1123.
39. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013; 190:3670-3678.
40. Mahdi H, Fisher BA, Kallberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009; 41:1319-1324.
41. Knevel R, Klein K, Somers K, et al. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 2013; 73:2038-2046.
42. Mele DA, Salmeron A, Ghosh S, et al. BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 2013; 210:2181-2190.
43. Santiago C, Nguyen K, Schapira M. Druggability of methyl-lysine binding sites. J Comput Aided Mol Des 2011; 25:1171-1178.